Most Read Articles
Stephen Padilla, 5 days ago
Local clusters of the 2019 coronavirus disease (COVID-19) can be expected in countries with high travel volume from China before the lockdown of Wuhan and the institution of travel restrictions, according to a study in Singapore, wherein three initial clusters had been identified in February 2020: a tour group from China, a company conference, and a church.
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Product Highlight - Bisolvon

29 Mar 2019
  • Active Ingredient: Bromhexine hydrochloride 8 mg/5 mL (high strength).
  • Indications: Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.
  • Dosage & Administration: Adults and children over 12 years: 5 mL (1 tsp) 3 times daily. Children 6-12 years: 2.5 mL (1/2 tsp) 3 times daily.
  • General: At commencement of treatment, it may be necessary to increase the total daily dose up to 48 mg in adults.
    The syrup is sugar-free and alcohol-free therefore suitable for diabetics and small children.
    Patients being treated with Bisolvon should be notified of an expected increase in the flow of secretions.
    In acute respiratory indications, medical device should be sought if symptoms do not improve or worsen during course of therapy.
  • Presentation: Syrup(Choco-Cherry) 8 mg/5 mL x 60 mL x 1’s.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 5 days ago
Local clusters of the 2019 coronavirus disease (COVID-19) can be expected in countries with high travel volume from China before the lockdown of Wuhan and the institution of travel restrictions, according to a study in Singapore, wherein three initial clusters had been identified in February 2020: a tour group from China, a company conference, and a church.
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.